Interventions for Tuberculosis Control and Elimination
Next
Previous
First
Last
Rifampicin has a crystalline structure and its manufacturing may negatively influence the pharmacokinetic properties of the drug.
Similarly, just changing the excipient and the manufacturing process changes the pharmacokinetics of rifampicin.
It is therefore critical to require bioavailability studies from potential suppliers. Such studies should preferably be performed by an independent university.
